FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape

Kriti Mittal; Monika Joshi

doi:10.1016/j.medj.2023.12.008

FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape

Med. 2024 Mar 8;5(3):176-178. doi: 10.1016/j.medj.2023.12.008.

Authors

Kriti Mittal¹, Monika Joshi²

Affiliations

¹ University of Massachusetts Medical Center, Worcester, MA, USA.
² Penn State Cancer Institute, Hershey, PA, USA. Electronic address: mjoshi@pennstatehealth.psu.edu.

PMID: 38460495
DOI: 10.1016/j.medj.2023.12.008

Abstract

As frontline treatment of advanced urothelial cancer (UC) evolves, optimal sequencing of subsequent therapies remains unclear. The phase 3 THOR trial compared the efficacy of erdafitinib to chemotherapy or immunotherapy in FGFR3/2-altered advanced UC. THOR offers valuable data informing sequencing strategies, reinforcing the need for molecular testing in UC.

MeSH terms

Carcinoma, Transitional Cell* / drug therapy
Humans
Immunotherapy
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Urinary Bladder Neoplasms* / drug therapy